MiRNA505/NET1 Axis Acts as a CD8+ T-TIL Regulator in Non-Small Cell Lung Cancer

被引:5
|
作者
Zhu, Pengyuan [1 ]
Liu, Zhenchuan [2 ]
Huang, Haitao [1 ]
Zhong, Chongjun [1 ]
Zhou, Yongxin [2 ]
机构
[1] Nantong Univ, Dept Thorac & Cardiovasc Surg, Affiliated Hosp 2, Nantong 226001, Jiangsu, Peoples R China
[2] Tongji Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Tongji Hosp, Shanghai 200065, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2020年 / 13卷
基金
中国博士后科学基金;
关键词
lung adenocarcinoma; miR-505-3p; NET1; CD8(+) T-TILs; TME; EXPRESSION; PROLIFERATION; METASTASIS; ACTIVATION; MICRORNA; GENOMICS; PATHWAY; MARKER; RNAS;
D O I
10.2147/OTT.S265859
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Lung adenocarcinoma (LUAD), which is the most important and common subtype of non-small cell lung cancer (NSCLC), is highly heterogeneous with a poor prognosis and poses great challenges to health worldwide. MicroRNAs (miRNAs) are regulators of gene expression with recognized roles in physiology and diseases, such as cancers, but little is known about their functional relevance to CD8(+) T cell infiltration regulation in the tumor microenvironment (TME) of NSCLC patients, especially LUAD patients. Methods: Bioinformatic analysis was used to analyze TCGA data. RT-PCT, Western blot, luciferase assay and immunohistochemistry were used to detect the expression levels and bindings of genes and miRNA. ELISA and cytotoxic assay were used to evaluate CD8(+) T cell function. Results: In this study, bioinformatic analysis unveiled the miR-505-3p/NET1 pair as a CD8(+) T-tumor-infiltrating lymphocyte (TIL) regulator. Then, we confirmed the bioinformatic results with LUAD patient samples, and NET1 was shown to be a direct target of miR-505-3p in a luciferase assay. Functional experiments demonstrated that miR-505-3p enhanced CD8(+) T-TIL function, while NET1 impaired CD8(+) T-TIL function and partly reversed the effects of miR-505-3p. The observed effects might be exerted via the regulation of immunosuppressive receptors in T cells. Discussion: Our study may provide novel insights into LUAD progression related to the TME mechanism and new possibilities for improving adoptive immunotherapy.
引用
收藏
页码:9785 / 9795
页数:11
相关论文
共 50 条
  • [1] Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells
    Jiang, Ze-Bo
    Xu, Cong
    Wang, Wenjun
    Zhang, Yi-Zhong
    Huang, Ju-Min
    Xie, Ya-Jia
    Wang, Qian-Qian
    Fan, Xing-Xing
    Yao, Xiao-Jun
    Xie, Chun
    Wang, Xuan-Run
    Yan, Pei-Yu
    Ma, Yu-Po
    Wu, Qi-Biao
    Leung, Elaine Lai-Han
    PHARMACOLOGICAL RESEARCH, 2021, 169
  • [2] Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis
    Jiang, Ze-Bo
    Huang, Ju-Min
    Xie, Ya-Jia
    Zhang, Yi- Zhong
    Chang, Chan
    Lai, Huan-Ling
    Wang, Wenjun
    Yao, Xiao-Jun
    Fan, Xing-Xing
    Wu, Qi-Biao
    Xie, Chun
    Wang, Mei-Fang
    Leung, Elaine Lai-Han
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [3] Insufficient CD100 shedding contributes to suppression of CD8+ T-cell activity in non-small cell lung cancer
    Wang, Hong-Min
    Zhang, Xiao-Hong
    Ye, Li-Qun
    Zhang, Kai
    Yang, Ning-Ning
    Geng, Shen
    Chen, Jing
    Zhao, Shun-Xin
    Yang, Kang-Li
    Fan, Fei-Fei
    IMMUNOLOGY, 2020, 160 (02) : 209 - 219
  • [4] NFATc1 Promotes Antitumoral Effector Functions and Memory CD8+ T-cell Differentiation during Non-Small Cell Lung Cancer Development
    Heim, Lisanne
    Friedrich, Juliane
    Engelhardt, Marina
    Trufa, Denis I.
    Geppert, Carol I.
    Rieker, Ralf J.
    Sirbu, Horia
    Finotto, Susetta
    CANCER RESEARCH, 2018, 78 (13) : 3619 - 3633
  • [5] Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
    Donnem, Tom
    Hald, Sigurd M.
    Paulsen, Erna-Elise
    Richardsen, Elin
    Al-Saad, Samer
    Kilvaer, Thomas K.
    Brustugun, Odd Terje
    Helland, Aslaug
    Lund-Iversen, Marius
    Poehl, Mette
    Olsen, Karen Ege
    Ditzel, Henrik J.
    Hansen, Olfred
    Al-Shibli, Khalid
    Kiselev, Yury
    Sandanger, Torkjel M.
    Andersen, Sigve
    Pezzella, Francesco
    Bremnes, Roy M.
    Busund, Lill-Tove
    CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2635 - 2643
  • [6] MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer
    Zhang, Cailian
    Ge, Shengli
    Hu, Cailian
    Yang, Ning
    Zhang, Jinran
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2013, 45 (12) : 1055 - 1061
  • [7] Advances of HIF-1α/glycolysis axis in non-small cell lung cancer (Review)
    Shi, Yuxuan
    Lin, Xiangyi
    Wang, Jinwen
    Zhou, Zhiqing
    Chen, Sijie
    Chen, Guoan
    ONCOLOGY REPORTS, 2024, 51 (04)
  • [8] Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer
    Horton, Brendan L.
    Morgan, Duncan M.
    Momin, Noor
    Zagorulya, Maria
    Torres-Mejia, Elen
    Bhandarkar, Vidit
    Wittrup, K. Dane
    Love, J. Christopher
    Spranger, Stefani
    SCIENCE IMMUNOLOGY, 2021, 6 (64)
  • [9] Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
    Zhang, Yan
    Huang, Shengdong
    Gong, Dejun
    Qin, Yanghua
    Shen, Qian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2010, 7 (05) : 389 - 395
  • [10] Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer
    Mariscal, Javier
    Alonso-Nocelo, Marta
    Muinelo-Romay, Laura
    Barbazan, Jorge
    Vieito, Maria
    Abalo, Alicia
    Gomez-Tato, Antonio
    de Cal Maria de los Angeles, Casares
    Garcia-Caballero, Tomas
    Rodriguez, Carmela
    Brozos, Elena
    Baron, Francisco
    Lopez-Lopez, Rafael
    Abal, Miguel
    SCIENTIFIC REPORTS, 2016, 6